

Index

Note: Page numbers of article titles are in **bold face** type.

ACROSCLEROSIS, 6–7, 246
Adrenocorticotrophic hormone, 289–290
Age-specific incidence and mortality in PSS, 16–18
Alkylating agents, 291–293
American Rheumatism Association (ARA), 27
Angiographic abnormalities in kidney, 172–173
Arrhythmias, 138–139
Arterial thrombi in kidney, 171–172
Atrophoderma Pasini–Pierini, 226
Azotaemia, 169–170

BLEOMYCIN-INDUCED pseudoscleroderma, 9, 255–256
Bullous morphoea, 236

CALCERGY, 57
Calcinosis, 54–58
Calciphylaxis, 56–57
Captopril, 178, 272–273
Carcinoid syndrome, 249–250
Cardiac death, sudden, 140–141
Cardiac involvement in PSS, **131–149**
 clinical diagnosis and course of, 145–146
 clinical perspective, 131–132
 effect of *D*-penicillamine on, 282
 historical perspective, 131
Cardiovascular system, management of, 270–271, 294
Chemical-induced scleroderma-like conditions, 9
Chest pain, 140
Children, localized scleroderma in, 227–228
Chlorambucil, 293–295
Chromosomal abnormalities in PSS, **201–213**
Chromosomal instabilities—possible causes, 208–211
 production of breaks, 208–209
 repair of damage, 209–211
Classification and nomenclature of PSS, **5–13**, 16

Colchicine, treatment of PSS with, **294–302**
 clinical studies with, 295–298
 effect in localized scleroderma, 299–300
 effect on collagen metabolism, 295
 long-term effectiveness of, 298–299
 side effects of, 300

Collagen—
 biosynthesis of, 190, 192–196
 chromosomal instability and, 206–210
 content, 61–63, 186–189
 cross-links of, 189–192
 degradation of, 196–197
 effect of colchicine on metabolism of, 295
 electron microscopic appearance of, 186
 extractability of, 189
 genetically distinct types of, 192
 structure of, 192

Conduction disturbances, 138–139
Congestive heart failure, 139–140
Connective tissue, metabolism of in PSS, **185–200**

Corticosteroids, 289–290
CREST syndrome, 6–8, 21–22, 49–54, 58, 61, 64–65

Cutaneous involvement in PSS, clinical features and pathogenesis of, **49–79**

Cytogenetic observations—
 in other connective tissue disorders, 206
 in PSS patients and families, 202–204

DATA analysis of SCCS, 35–36
Demographic features of SCCS, 36–37
Diagnostic evaluations of SCCS, 32
Diffuse scleroderma, 49
Dyspnoea, 152

ELECTROMYOGRAPHY, 106–107
Endocardial disease, 141
Endothelial cell changes in kidney, 171, 173–176
Eosinophilic fasciitis, 10–11, 244–246
Epidemiology of PSS, **15–25**
 methodological considerations, 15–16

FACIAL hemiatrophy, 221–223

Familial occurrence PSS, 18–19
 Fasciitis, diffuse, with eosinophilia, 10–11,
 244–246
 Fibrin deposits in kidney, 173–176

GASTROINTESTINAL involvement in PSS,
 115–129
 Gastrointestinal tract—
 effect of chlorambucil on, 294
 effect of D-penicillamine on, 282–283
 management of, 268–269
 Generalized morphea, 223–224
 Geographical factors in epidemiology of
 PSS, 18
 Graft-versus-host disease, chronic, 236,
 250–251
 Guttate morphea, 217

HUTCHINSON–GILFORD syndrome, 246–247
 Hydroxyproline content of skin, 64–65
 Hypertension, 168–169

IMMUNOSUPPRESSIVE agents, in treatment of
 PSS, 289–294
 Intimal thickness in kidney, 171
 Ischaemia, effect of on connective tissue,
 197

KELOID morphea, 225–226
 Kidney involvement in PSS, 167–184
 angiographic abnormalities in, 172–173
 clinical manifestations of, 168–170
 electron microscopic findings in, 171–172
 endothelial cell changes in, 171
 epidemiology of, 167
 histopathological features of, 170–172
 immunohistological findings in, 172
 management of, 271–274
 pathogenesis of, 173–178
 therapy, 178–179

LARGE intestine in PSS, 124–126
 Lichen sclerosus et atrophicus, 216–217
 Linear scleroderma, 220–221
 Liver in PSS, 126
 Localized forms of scleroderma, 8–9,
 215–241
 and vitiligo, 226–227
 clinical features of, 217–228
 course and prognosis of, 233–235
 effect of colchicine on, 299–300
 epidemiology of, 215
 in children, 227–228
 laboratory findings in, 237–238
 management of, 238–239
 nomenclature and classification of,
 216–217
 origin and pathogenesis of, 236–237

pathology of, 228–233
 relation to PSS, 215–216
 ultrastructural studies of, 232–233

MANAGEMENT of PSS, 263–302
 Maximal oral aperture, 51, 53
 Melorheostosis, 257
 Microcirculation—
 clinical inspection, 84
 disorders of in PSS, 81–101
 functional abnormalities of, 90–91
 functional studies of, 84–85
 in vivo microscopy, 83–84
 in vivo observations and histopathological
 data, relationship between, 93–94
 morphological abnormalities of, 85–90
 Microvascular bed, definition of, 81–82
 Microvascular disturbances, treatment of,
 96–97
 Microvasculature in the pathogenesis of
 scleroderma, 94–96
 Mixed connective tissue disease (MCTD), 5,
 104, 110–111
 Morphea—
 bullous, 226
 generalized, 223–224
 guttate, 217
 keloid (nodular), 225–226
 plaque-like, 217
 subcutaneous, 224–225
 Muscle biopsy, 107–110
 Musculoskeletal system, management of,
 267–268
 Myocardial involvement, 132–141
 Myocardial lesions—
 clinical correlates of, 138
 pathogenesis of, 133–138

NATURAL history of PSS, 19–22
 Non-collagenous protein, 197–198

OCCUPATIONAL factors in PSS, 18
 Occupational pseudosclerodermas, 256–257
 Oesophagus in PSS, 115–120
 clinical features of, 115–116
 complications of, course and prognosis,
 119
 diagnostic procedures in, 116–118
 pathology and pathophysiology of,
 118–119
 treatment of, 119–120, 268
 Overlap syndromes, muscle involvement in,
 110

D-PENICILLAMINE, in treatment of PSS, 97,
 277–288
 efficacy of, 279, 280–283
 principles of, 278–280
 side effects of, 283–285

Pericardial disease, 141
Pharmacological agents in management of PSS, 264, 265-266
Phenylketonuria, 75, 252-253
Photoelectric plethysmography, 84
Plaque-like morphoea, 217
Polymyositis-dermatomyositis (PM/DM), 18, 29, 30, 32, 36-37, 38, 103-105, 109-111
Porphyria cutanea tarda, 251-252
Procollagen, 186, 190, 192-195
Progeria, 246-248
Proteinuria, 168
Pseudoscleroderma, 10, 11, 243-261
 occupational, 256-257
Pulmonary function, 157-163
Pulmonary hypertension, 141-145, 156-157
Pulmonary involvement in PSS, 151-166
 clinical features of, 152-153
 effect of chlorambucil on, 294
 effect of D-penicillamine on, 282
 management of, 270
 pathological findings, 154-156
 roentgenographic aspects of, 153-154
Purine antimetabolites, 293

RACE-SPECIFIC incidence and mortality in PSS, 16-18
Raynaud's phenomenon, 7, 8, 15, 30, 94-96, 246, 249
 management of, 266-267
 cytogenetic observations on, 202-205
Relation between localized and progressive systemic sclerosis, 215-217
Renal blood flow, reduction of, 176
Renal disease—
 acute, 170-171
 chronic, 171
Renal system—
 effect of colchicine on, 283
 management of, 271-274
Renal transplantation in PSS, 179
Renin-angiotensin system in renal disease, 177-178
Roentgenographic aspects in pulmonary involvement, 153-154

SARALASIN, 272
Scleredema, 243-244
Scleroderma—
 evolution of, 49-54
 histological changes in, 58-61
 microvasculature in the pathogenesis of, 94-96
Scleroderma Criteria Cooperative Study (SCCS), method and preliminary results of, 27-48
 materials and methods, 29-36

preliminary preparations, 28-29
 results, 36-43
Scleroderma-like conditions, chemical-induced, 9
Scleroderma *en coup de sabre*, 6, 217, 222
Scleroderma, localized—*see* Localized forms of scleroderma
Sclerodermatomyositis, 5
Sclerodermatosus skin changes, classification of disorders with, 15
Scleromyxoedema, 253-255
Serum muscle enzymes, 104-105
Sex-specific incidence and mortality in PSS, 16-18
Skeletal muscle involvement in PSS, 103-113
 clinical course of, 110-111
 historical note, 103-104
 laboratory data, 104-110
 management of, 267-268
 physical examination in, 104
 symptoms of, 104
 therapy in, 110-111
Skin—
 effect of chlorambucil on, 294
 effect of D-penicillamine on, 280-281
 management of, 267
Skin biopsies—
 chemical analysis of—
 hydroxyproline content, 64-65
 water content, 64
 weights of, 71, 72, 73, 75
 changes in, 65-66
Skin blood vessels, examination of, 83-84
Skin thickening—
 pathogenesis of, 66-76
 symmetry of, 63-64
Skin thickness, 61-63
Small intestine in PSS, 120-124
 clinical features, 120-122
 complications, course and prognosis, 123
 pathology and pathophysiology, 122-123
 treatment, 123-124
Smooth muscle cells in kidney, 171
Stomach in PSS, 120
Study design of SCCS, 29-30
Subcutaneous morphoea, 224-225
Survival studies in PSS, 19-22
Systemic lupus erythematosus (SLE), 16, 17, 18, 19, 30, 36-38

TELANGIECTASES, 43, 52, 93
 relationship with microvascular abnormalities, 91-93
Teprotide, 272
Thibierge-Weissenbach syndrome, 7, 58
Thrombosis, 173-176

URINE creatine and creatinine, 106

VENOUS occlusion plethysmography, 84
Vinyl chloride, 9
Viral infection, possible cause of
chromosome damage, 208-209

Vitiligo, localized scleroderma and,
226-227

WERNER's disease, 248-249

Index

Note: Page numbers of article titles are in **bold face** type.

ANALGESICS, 354

Ankylosing spondylitis, 704
see also under names of specific drugs

Anti-inflammatory drugs, classification of, 354–356

Aspirin, **499–539**
absorption, distribution and excretion, 500–508
anti-inflammatory effects, 513–516
antipyretic effects, 513
aspirin allergy, 517–519
chemistry, 499
drug interactions, 516–517
effects on blood and blood coagulation, 510–513
history, 500
immunological effects, 510
metabolic and endocrine effects, 508–509
mixtures in common use, 503–504
newer salicylate preparations, 523–524
preparations in common use, 502

Azapropane, **465–480**
adverse reactions, 476–477
chemistry, 465–466
dosage and administration, 477–478
indications, 473–474
gout, 474
OA, 474
RA, 473–474
shoulder pain, 474

pharmacokinetics and metabolism, 469–470

pharmacological profile, 466–469

safety and tolerance, 474–475

toxicity, 471–473

BENOXAPROFEN, **398–410**

chemistry, 399
effect on GI bleeding, 401–403
effectiveness in man, 403–406
in vitro effects, 400
metabolism in man, 401
pharmacology and toxicology, 399–400

Bone, Paget's disease of, *see* Paget's disease of bone, drug treatment of

CALCIFIC periarthritis, drug treatment of, 704–705

Chemistry, *see under* names of specific drugs

Chryotherapy in RA, **631–640**
dosage, 633–634
indications and contraindications, 638–639
pharmacology, 631–633
toxic effects, 634–637

Classification of anti-rheumatic drugs, 353–357

Clinical studies, *see under* names of specific drugs

DENTAL pain, use of diflunisal, 718

Diclofenac sodium, *see* Voltarol

Diflunisal, **707–731**
adverse reactions, 722–726
chemistry, 707–708
clinical actions, 715–722
contraindications, 728
dosage, 728
indications, 728
interactions, 722
non-responders, 721–722
ototoxicity, 727
pharmacokinetics and metabolism, 713–715
pharmacology, 708–712
special safety studies, 726
toxicology, 712–713

Drug treatment, choice of in RA and other rheumatic diseases, **697–706**

FAMILIAL Mediterranean fever, drug treatment of, 705

Fenoprofen, **393–398**
chemistry, 393–394
pre-clinical pharmacology, 394–395
studies related to safety, 395–397
trials in osteoarthritis, 397–398

Flurbiprofen, **359–379**
adverse reactions, 375
chemistry, 359–360
clinical actions, 371–374

Flurbiprofen (contd.)
 clinical uses, 376
 drug interactions, 373–374
 gastrointestinal tolerance, 374
 general pharmacology, 364–365
 mechanisms in action, 363–364
 pharmacokinetics and metabolism in man, 367–368
 specific pharmacology, 361–362
 toxicology, 365–366

GOUT, drug treatment of, 657–672
 acute gouty arthritis, 659–662
 associated conditions, management of, 668–669
 colchicine, 662–664
 idiopathic hyperuricaemia, 669–670
 inhibitor of urate biosynthesis, 666–668
 prevention of progression of degenerative changes in articular and non-articular tissues, 662–668
 uricosuric agents, 664–666

IBUPROFEN, 359–379
 adverse reactions, 374–375
 chemistry, 359
 clinical actions, 368–371
 clinical uses, 376
 drug interactions, 371
 gastrointestinal tolerance, 374
 general pharmacology, 364
 mechanisms of action, 362–363
 pharmacokinetics and metabolism in man, 366–367
 specific pharmacology, 360–361
 toxicology, 365

Indomethacin, 541–552
 adverse reactions, 547–548
 chemistry and pharmacology, 541–543
 clinical actions, 544–547
 acute musculoskeletal disorders, 546
 ankylosing spondylitis, 545
 gout, 545–546
 OA, 544
 RA, 544–545
 clinical use, 548–550
 dosage, 550
 drug interactions, 549–550
 pharmacokinetics, 543

JUVENILE arthritis, drug treatment of, 703

KETOPROFEN, 381–391
 biological tolerance, 387
 clinical tolerance, 385–387
 evaluation of activity in clinical practice, 383–385
 ankylosing spondylitis, 384
 gout, 384

OA of hip and knee, 384
 RA, 383–384

in animal pharmacology, 381

metabolism and pharmacokinetics in man, 382–383

mode of action, 381–382

open studies, 385

LEVAMISOLE, 603–629
 adverse reactions, 618
 chemistry, 604–605
 clinical actions, 611–618
 RA, 611–617
 biological effects, 614–615
 clinical effects, 611–614
 factors influencing responsiveness, 617
 immunological effects, 615–617
 other rheumatic diseases, 618

contraindications, 623
 dosage, 622
 pharmacokinetics, 610–611
 pharmacology, 605–610
 toxicology, 610
 use, 622–624

Low back pain, use of diflunisal, 719

Lupus erythematosus, systemic, *see* **Systemic lupus erythematosus**

MALIGNANT disease, pain and the use of diflunisal, 719

Metabolism, *see under* names of specific drugs

NAPROXEN, 411–426
 chemistry, 411–412
 drug interactions, 416–417
 pharmacokinetics and metabolism, 415–416
 pharmacology, 412–414
 therapeutic trials, 417–421
 toxicology, 414–415

Non-steroidal anti-inflammatory drugs, classification of, 354–355

OSTEITIS deformans, *see* **Paget's disease of bone**

Osteoarthritis, drug treatment of, 702–703
see also under names of specific drugs

PAGET'S disease of bone, drug treatment of, 673–695
 analgetics, 677
 biochemical features, 674–675
 calcitonins, 677–683
 combined treatment with diphosphonates, 688–689
 cause, 674
 clinical features, 675

Page's disease of bone (*contd.*)
diphosphonates, 683–689
drug treatment, 676–677
histological features, 674
indications, 676–677
mithramycin, 689–690
nature of Page's disease, 673–677
occurrence, 673–674
radiology and scintigraphy, 674
treatment, other aspects of, 691–693

Palindromic rheumatism, drug treatment of, 704

Penicillamine, 569–601
adverse effects, 587–593
chemistry, 571–572
comparison with other drugs, 586
dosage, 593–594
drug interactions, 592–593
effects on animal models of RA, 576–577
factors affecting response, 586–587
historical development, 569–570
indications, 593
pharmacokinetics, 577–580
pharmacology, 572–576
therapeutic role, 580–586
cystinuria, 580
juvenile chronic polyarthritis, 585
palindromic rheumatism, 585
progressive systematic sclerosis, 585–586
RA, 580–585
seronegative polyarthritis, 585
Wilson's disease, 580

toxicology, 577

use in RA, 593–595

Pharmacokinetics, *see under* names of specific drugs

Pharmacology, *see under* names of specific drugs

Polymyalgia rheumatica, drug treatment of, 704

Postoperative pain, use of diflunisal, 718–719

Post-traumatic pain, use of diflunisal, 719

Psoriatic arthropathy, drug treatment of, 703–704

REITER's disease, drug treatment of, 704–705

Rheumatoid arthritis and other rheumatic diseases, drug treatment of, 697–706
acute calcific periarthritis, 704–705
ankylosing spondylitis, 704
conditions requiring intra-articular or local steroid therapy, 705
familial Mediterranean fever, 705
juvenile arthritis, 703
osteoarthritis, 702–703
palindromic rheumatism, 704

polymyalgia rheumatica, 704
psoriatic arthropathy, 703–704
RA, 697–702
phase I: relief of symptoms, 700
phase II: control of the disease, 700–702

Reiter's disease, 704–705
see also under names of specific drugs

SALICYLATES, 499–539

absorption, distribution and excretion, 500–508
anti-inflammatory effects, 513–516
antipyretic effects, 513
aspirin allergy, 517–519
aspirin and the GI tract, 519–523
chemistry, 499
drug interactions with aspirin, 516–517
effects on blood and blood coagulation, 510–513
history, 500
immunological effects, 510
metabolic and endocrine effects, 508–509
newer salicylate preparations, 523–524
preparations in common use, 502

SLE, *see* Systemic lupus erythematosus

Sports injuries, drug treatment of, 705

Sulindac, 553–568

adverse effects, 563–565
chemistry and pharmacology, 553–555
clinical actions, 557–562
acute gout, 560
acute painful shoulder, 559–560
ankylosing spondylitis, 561
OA, 557–559
RA, 561–562

Systemic lupus erythematosus, treatment of, 641–655

adverse drug reactions and allergies, 642–648
antimalarials, 645–646
aspirin, 643–644
corticosteroids, 646–648
immunosuppressive agents, 648
NSAIDs, 644

cyclosporin A, 651
levamisole, 649–651
monitoring disease activity, 651–652
prostaglandin E, 651
pulse steroid therapy, 648–649
thoracic duct drainage, 649

TOLMETIN sodium, 481–497


clinical use, 490–493
ankylosing spondylitis, 493
non-articular rheumatism and soft tissue disease, 493
OA, 493
RA, 490–493

Tolmetin sodium (*contd.*)
 dosage and administration, 494-495
 drug interactions, 494
 non-articular rheumatism and soft tissue
 diseases, 486-487
OA, 486
pharmacokinetics, 490
pharmacology, 488-490
RA, 484-486
 juvenile, 485-486
untoward interactions, 494
Toxicology, *see under* names of specific
 drugs

VOLTAROL, 427-464
 adverse reactions, 459-460
 blood coagulation factors and, 441-442
 clinical studies in ankylosing spondylitis,
 451-452
 clinical studies in OA, 448-451
 clinical studies in RA, 444-447
 clinical trials, 452-455

OA, 454
RA, 453-454
drug comparisons, 444-450
drug interactions, 439-450, 461
effect on binding of L-tryptophan to
 plasma proteins, 442-443
effects of diclofenac sodium in the human
 GI tract, 443-444
laboratory studies of haemopoietic,
 hepatic and renal function, 457-458
long-term studies in rheumatic diseases,
 455-457
OA, 456
RA, 455-456
pharmacokinetic studies in elderly
 subjects, 440-441
pharmacokinetic studies in patients in
 renal failure, 441
pharmacokinetics, metabolism and
 metabolites, 433-440
pharmacology, 429-431
pharmacology of metabolites, 431-433
toxicity, 433





Index

Note: Page numbers of article titles are in **bold** face type.

AB ARTICULAR gout, 810-811
Adventitious bursae, 886
Angiography, value of in temporal arteritis, 785-786
Ankle, acute capsular strains of, 934-935
Ankylosing spondylitis, enthesitis in, 865
Anterior tibial tunnel syndrome, 952
Anti-inflammatory agents, in treatment of soft tissue trauma, 929-930
Arthropathies, metabolic, 866-869

BAKER'S cyst, 897
Bicipital tendinitis, 895
Bursae—
 'adventitious', 886
 anatomical background, 883-885
 and bursitis, 883-899
 chronic non-infectious inflammatory disease of, 889
 development and normal structure of, 885-886
 historical background, 883-885
 iliopectineal, 896
 iliopsoas, 896
 infection of, 886-887
 antibiotic-induced candidaemia, 887
 brucellar, 887
 septic, 886
 sporotrichosis, 887
 infrapatellar, 897
 popliteal, 897
 posterior gastrocnemiosemimembranosus, 897
 pseudotumoral lesions of, 889
 sub-Achilles, 897
 subcutaneous prepatellar, 897
 and tendons, and tendon sheaths, lesions of, 883-895

Bursitis—
 anserine, 897
 bicipital, 895
 calcific, 888
 subacromial, 888
 in area of heel and foot, 897-899
 in area of hip joint, 895-897

in knee region, 897
of specific bursae, 889-899
 hyoid bursa, 889
 cervical interspinous bursa, 889-891
 lumbar interspinous bursa, 889-891
 scapular bursa, 893-894
 subacromial and upper limb bursae, 895
 septic, 886
 subsartorial, 897
 trochanteric, 896

CALCERY, 915
Calcification, localized, of soft tissue, 818-819
Calcific bursitis, 888
 subacromial, 888
Calcific periarthritis, 813-818
 cause of inflammation in, 817
 clinical features of acute form of, 816
 localized variants of, 817
Calcific tendinitis, and tenosynovitis, 915-917
Calcifying collagenolysis, 815
Calcinosis—
 generalized soft tissue, 813-815
 tumoral, 888
'Calciphylaxis', 915
Carpal tunnel syndrome, 942-946
 relationship with polymyalgia, 778
Cerebrotendinous xanthomatosis, 915
Cervical rib syndrome, 950-951
Classification of soft tissue rheumatism, 739-742, 745-748
Collagen, structure and synthesis of, 834-835
Common peroneal nerve, entrapment of, 951-952
Connective tissue diseases, associated with calcinosis, 814
Cramp, 873-881
 at rest, 875
 causative factors, 877-878
 definition of, 873-878
 induced by treatment, 876-877
 chronic haemodialysis, 876
 morphine, 877

Cramp—(*contd*)
 phenothiazine, 877
 saline diuretics, 876
 terbutaline, 877
 on effort, 874–875
 secondary to disease, 876
 treatment of, 878–881

Crystal deposition disease—
 AB articular gout, 810–811
 and the soft tissues, 807–822
 formation of crystal deposits, 808–809
 hydroxyapatite deposition, 813–818
 in connective tissues, 808
 pyrophosphate crystals, 812–813
 urate deposition, 810–811

Crystal-induced damage to soft tissues, 810

Crystal-induced inflammation, pathogenesis of, 810

Cytotoxic drugs, in pulmonary fibrosis, 843–844

DEGENERATIVE bone and joint disease, relationship with enthesopathies, 864

Dermatomyositis, calcinosis in, 814

Diagnostic categories of soft tissue rheumatism, 746–748

Drug-induced fibrosis, 842–843

Dupuytren's disease, and contracture, 837–840
 aetiology of, 837–838
 clinical features of, 838
 histological changes in, 838–840
 prevalence, 837

ENDORPHIN insufficiency, relative, fibrosis and, 830

Entheses, 857–872
 anatomical characteristics of, 857–858
 changes of, with age, 859
 functional characteristics of, 858–859
 pathological changes of, 859

Enthesopathy, 857–872
 aetiopathogenesis of, 860
 causing change in function, 860–861
 clinical manifestations of, 861
 enthesopathic component in inflammatory rheumatic disease, 865–866
 relationship with degenerative bone and joint diseases, 864
 relationship with periarthritis, 864–865
 treatment of, 869–870
 x-ray manifestations of, 861

Entrapment neuropathies, 941–955

Epidemiology of soft tissue rheumatism, 743–753
 localized forms of rheumatism, 745
 regional differences in symptom description, 744–745

Ethosuximide, in production of fibrosis, 843

Extra-articular calcification, 813–818

FAMILIAL beta-hyperlipoproteinaemia, 914–915

Fascia, deep, trauma to, 927

Fasciitis—
 a discrete entity?, 835
 anatomical considerations of, 833
 and fibrosis, 833–855
 eosinophilic, 849
 nodular, 836–837
 pseudosarcomatous, 836–837

Fibrosis—
 drug-induced, 842–843
 ethosuximide, 843
 methysergide, 842
 practolol, 842–843
 fasciitis and, 833–855
 idiopathic, 840–842
 inflammation and, 833–834
 mediastinal, 841–842
 retroperitoneal, 841

Fibrositis—
 as a disorder of pain modulation, 823–832
 as a pain amplification syndrome, 830
 classification of, 826–829
 deep hyperalgesia in, 829
 management of fibrositic rheumatoid patient, 830–831
 primary, 826–827
 referred pain in, 829
 relative endorphin insufficiency and, 827–829
 sleep disturbance associated with, 827–829
 therapy of, 831–832

GARGOYLISM, 911

Generalized rheumatism, polymyalgia rheumatica, and its differential diagnosis, 775–795

Gout, 911–914

HAEMOCHROMATOSIS, 912

Health service, utilization of by patients, 748–751

Heredo-familial vascular and articular calcification, 815

Hexamethonium, in pulmonary fibrosis, 843

Hydroxyapatite crystal deposition, 813–817
 in tendons, 915–917

Hyoid bursa, bursitis of, 889

Hyperlipidaemias, 818

IDIOPATHIC fibrosis, 840–842
 mediastinal fibrosis, 841–842
 Peyronie's disease, 840–841
 retroperitoneal fibrosis, 841

Iliopsoas bursa, 896

Incapacity for work, due to soft tissue rheumatism, 749-750

Infective tenosynovitis, 907

Inflammatory rheumatic diseases, enthesopathic component in, 865-866

Interspinous bursae, 889-891

JOINT diseases, in polymyalgia rheumatica, 777

KNEE, ligamentous injuries of, 933-934

 LIGAMENTS, trauma to, 927, 930
 ankle: acute capsular strains, 934-935
 complete tear, 932
 partial tear, 932
 posterior cruciate, 933-934
 shoulder—
 dislocation of, 932-933
 subluxation of, 933
 sprains of knee ligament, 933

Lipocalcinosis granulomatosis, 815

Local forms of rheumatism, 745

Localized classification of soft tissue rheumatism, 815-819

MEASUREMENT of pain, 756-769

Median nerve, compression of, 942-946

Meniscus, tearing of, 935-936

Meralgia paraesthesia, 953

Metabolic arthropathies, 866-869

Metabolic tendinopathies, 911-914

Methysergide, in production of fibrosis, 842

Morquio's syndrome, 912

Morton's metatarsalgia, 953-954

Muscle—
 injuries to, 936-938
 trauma to, 927

Myositis ossificans progressiva, 815

NEUROPATHIES, entrapment, 941-955

Nitrofurantoin, in pulmonary fibrosis, 844

Nodular fasciitis, 836-837
 diagnosis of, 836-837
 management of, 836-837
 pathology of, 836

Nodular tenosynovitis, localized, 914

OCHRONOSIS, 915

Osteoarthritis, and polymyalgia rheumatica, 777-778

PAIN—
 as a condition, 755
 as a parameter, 756-769
 elicited, 756
 spontaneous, 756-769
 as a symptom, 755-756
 management of, 755

Pain Amplification Syndrome, 823

fibrositis as a, 830

Pain modulation, 'fibrositis' as a disorder of, 823-832

Pain perception threshold, 755-773
 determination of by measurement of noxious stimulus and response to it, 764-769

Pain tolerance threshold—
 and pain perception threshold, clinical and experimental studies, 755-773
 deep pain, methods of eliciting, 758
 intra-arterial injections, 758
 intra-articular injections, 758
 pressure devices, 758
 determination of, 757-761
 skin pain, determination of tolerance to, 757
 blister technique, 758
 bradykinin, intradermal injection of, 758
 electrical stimulation, 757, 761
 histamine, intradermal injection of, 758
 hot-plate application, 757
 infra-red application, 757
 prostaglandin, intradermal injection of, 758
 tourniquet technique, 758, 761

Periarthroses, relationship with enthesopathies, 864-865

Pigmented villonodular tenosynovitis, 914

Polymyalgia rheumatica—
 abnormal laboratory test results in, 760-781
 plasma viscosity, 780
 raised ESR, 780
 aetiology of, 781-782
 age-group affected, 776
 characteristics of, 776-780
 delays in diagnosis of, 779-780
 differential diagnosis of, 775-795
 bone disease—
 osteomalacia, 789
 osteoporosis, 789
 Paget's disease, 789
 senile hyperostotic ankylosis of the spine, 789
 infection antedating, 789
 joint diseases—
 osteoarthritis, 790
 rheumatoid arthritis, 790
 systemic lupus erythematosus, 790
 muscle disease, 791
 neoplastic disease, 790-791
 other diseases, 791
 genetic factors and familial aggregation, 782
 incidence of, 776
 pathogenesis of, 781-782
 symptoms and signs of—

Polymyalgia rheumatica—(contd)
 associated with liver, 779
 carpal tunnel syndrome, 778
 general health, 779
 muscle symptoms, 778–779
 synovitis, 777–778
temporal angiography for, 785
treatment, 786–788
 dose of corticosteroid, 786–787
 duration of, 787
 side effects of, 787–788

Practolol, in production of fibrosis, 842–843

Proctalgia fugax, 873

Progressive systemic sclerosis, 847–849

Pseudosarcomatous fascitis, 836–837
 diagnosis of, 836–837
 management of, 836–837
 pathology of, 836

Pseudotumoral lesions of the bursae, 889

Psoriatic arthritis, and calcaneal enthesitis, 866

Psychogalvanic skin reflex (PSR), 766–769

Psychogenic rheumatism, 797–805
 symptoms of—
 benign dorsalgia, 799
 cervicocranial, 800
 coccydynia, 801
 nocturnal acroparaesthesia, 800–801
 pain in the xiphisternum, 801
 restless legs, 801
 treatment of, 803–805

Psychogenic syndromes associated with organic disease, 802
 psychological changes in, 802

Pulmonary fibrosis, drug-induced, 843–844

PVC, disease associated with manufacture of, 844–847

Pyrophosphate crystal deposition, 812–813

RADIAL nerve, entrapment of, 949–950

Raynaud's phenomenon, and dermal thickening, in manufacture of PVC, 844–847

Reiter's syndrome, and enthesitis of the calcaneum, 806

Rheumatoid arthritis, tenosynovitis and tendinitis associated with, 907–911

Rotator cuff lesion, 905

SCAPULAR bursae, bursitis of, 893–894

Sciatic plexus, entrapment lesions of, 951

Scleroderma, 813, 814

Shoulder, injury to ligaments, 932–933

Sickness absence from work, due to soft tissue rheumatism, 750

'Snapping scapula', 893–894

Soft tissue calcification, generalized, 814–815

Soft tissue injuries—

anti-inflammatory agents in treatment of, 929–930

immediate care of, 928–929
 physical therapy of, 930

Soft tissue rheumatism—
 concept and classification of, 739–742
 in the community, 743–753
 symptom experience of, 744

Soft tissue trauma, sprains, strains, etc., 927–939
 biochemistry of, 929

Sprains, 927, 932
 of the knee, 933

Stenosis, of the tendon sheath, 903–905

'Stitch', 873

Strains, 927–939

Subacromial bursa, 895

Subdeltoid bursa, 895

Sural nerve, entrapment lesions of, 953

Systemic sclerosis, 847–849

TARSAL tunnel syndrome, 952–953

Temporal arteritis—
 history of, 775–776
 incidence of, 776
 pattern of, 785
 relationship with polymyalgia rheumatica, 775, 784

Tender points, in fibrosis, 824–826

Tendinitis, 899–917
 associated with RA, 907–911
 bicipital, 895
 calcific, 915–917
 posterior tibial, 906

Tendons, 899–917
 blood supply to, 900
 function of, 899
 rupture of, and repair, 901–903
 shoulder, lesions of, 905–907
 structure of, 899–900

Tendon sheaths—
 infections of, 907
 tumorous conditions of, 914–915

Tenosynovitis, 899–917
 associated with RA, 907–911
 calcific, 915–917
 peroneal, 906
 rotator cuff lesion, 905

Thoracic outlet syndrome, 950–951

Tophi, crystal, effects of, 811–812

Trigger finger, 903–905

Tumoral calcinosis, 815

ULNAR nerve, entrapment of, 946–948

Urate crystal deposition, 810–811

VINYL CHLORIDE diseases, 844–847

EX

of,

IC.,

ca,